lymphoid cells

[Intellia Therapeutics, Inc.] Intellia Therapeutics, Inc., a company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., a company dedicated to developing optimally engineered NK cell therapies to treat cancer, announced a licensing and collaboration agreement.

[Nature Communications] Researchers demonstrated how direct and indirect contact with allogenic MSCs improves regulatory T cells' (Tregs) potential for accumulation of immunosuppressive adenosine and suppression of conventional T cell proliferation, making them more potent therapeutic tools.

[Endocrine Journal] Researchers investigated the therapeutic effect of human umbilical cord MSCs on experimental autoimmune thyroiditis (EAT) and the underlying mechanisms by utilizing a porcine thyroglobulin-induced EAT rat model.

[Cell Research] T cells engineered with T cell receptors (TCRs) from naturally occurring tumor antigen-specific T cells in a patient will target personal tumor-specific antigens in their tumor.

[Legend Biotech Corporation] Legend Biotech Corporation achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel, a B cell maturation antigen-directed CAR-T therapy.

[Molecular Therapy] Researchers are now studying how to expand CAR T s technology beyond its use in conventional polyclonal αβ T cells to address limitations to the current therapy in cancer and applications beyond it.